PT  - JOURNAL ARTICLE
AU  - Tosta, Stephane
AU  - Giovanetti, Marta
AU  - Brandão Nardy, Vanessa
AU  - de Oliveira da Silva, Luciana Reboredo
AU  - Gómez, Marcela Kelly Astete
AU  - Lima, Jaqueline Gomes
AU  - Cardoso, Cristiane Wanderley
AU  - Silva, Tarcisio Oliveira
AU  - São Pedro Leal de Souza, Marcia
AU  - Dia, Pedro H. Presta
AU  - Fonseca, Vagner
AU  - Lourenço, José
AU  - Alcantara, Luiz Carlos Junior
AU  - Pereira, Felicidade
AU  - Leal, Arabela
TI  - Early genomic detection of SARS-CoV-2 P.1 variant in Northeast Brazil
AID  - 10.1101/2021.02.25.21252490
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.25.21252490
4099  - http://medrxiv.org/content/early/2021/03/01/2021.02.25.21252490.short
4100  - http://medrxiv.org/content/early/2021/03/01/2021.02.25.21252490.full
AB  - Tracking the spread of SARS-CoV-2 variants of concern is crucial to inform public health efforts and control the ongoing pandemic. Here, we report genetic evidence for circulation of the P.1 variant in Northeast Brazil. We advocate for increased active surveillance to ensure adequate control of this variant throughout the country.Article Summary Line Active genomic surveillance of SARS- CoV-2 suspected cases from recent travelers reveals the circulation of the P1 variant of concern in Bahia state, Northeast Brazil.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was financed by Laboratorio Central de Saude Publica da Bahia (LACEN BA) and Secretaria da Saude do Estado da Bahia (SESAB) and supported by Pan American Health Organization PAHO/WHO. We also thank Centro e Informacoes Estrategicas de Vigilancia em Saude (CIEVS) in the municipality of Salvador, Bahia. ST is supported by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brasil (CAPES), Finance Code 001. MG is supported by Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ). JL is supported by a lectureship from the Department of Zoology, University of Oxford. We also would like to thank all the authors who have kindly deposited and shared genome data on GISAID. A table with genome sequence acknowledgments can be found in Supplementary Table 1.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was approved by the Ethics Review Committee of the Federal University of Minas Gerais (CEP/CAAE: 32912820.6.1001.5149 approval number).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNewly generated SARS-CoV-2 sequences have been deposited in GISAID under accession numbers EPI_ISL_1067728 to EPI_ISL_1067738.